Biology:Pelacarsen

From HandWiki
Revision as of 22:04, 10 February 2024 by John Stpola (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Pelacarsen is an antisense therapy that is designed to reduce Lipoprotein(a) concentrations in people with high levels of the lipoprotein and who are at risk of cardiovascular disease.[1][2][3] It is developed by Ionis and Novartis.[4]

References

  1. ↑ Yeang, Calvin; Karwatowska-Prokopczuk, Ewa; Su, Fei; Dinh, Brian; Xia, Shuting; Witztum, Joseph L.; Tsimikas, Sotirios (March 2022). "Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol". Journal of the American College of Cardiology 79 (11): 1035–1046. doi:10.1016/j.jacc.2021.12.032. 
  2. ↑ Karwatowska‑Prokopczuk, Ewa; Lesogor, Anastasia; Yan, Jing-He; Hurh, Eunju; Hoenlinger, Angelika; Margolskee, Alison; Xia, Shuting; Tsimikas, Sotirios (January 2023). "Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects". Journal of Clinical Lipidology 17 (1): 181–188. doi:10.1016/j.jacl.2022.12.001. 
  3. ↑ Fernandez-Prado, Raul; Perez-Gomez, Maria Vanessa; Ortiz, Alberto (1 October 2020). "Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease". Clinical Kidney Journal 13 (5): 753–757. doi:10.1093/ckj/sfaa001. 
  4. ↑ Dharma, RanjithKumar (4 August 2023). "Ionis, Novartis to develop medicine for cardiovascular disease". https://www.pharmaceutical-technology.com/news/ionis-novartis-cardiovascular-disease/. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Pelacarsen&oldid=3529863"